Effect of Heliox on RSV Bronchiolitis
- Registration Number
- NCT03171142
- Lead Sponsor
- Wael Seliem
- Brief Summary
Helium is an inert gas with a density almost one-seventh of that of air. Based on its properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in resistance through narrowed airways and consequently decreases the work of breathing. Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21 oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in improving their oxygenation. Heliox will act as an additive therapy to improve oxygenation in patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV) and will decrease the need for more complicated therapies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 104
- Age fro 1 month till 2 years
- RSV acute bronchiolitis without any supplemental oxygen.
- oxygen supplement or mechanical ventilation requirement
- congenital anomalies of the heart
- chronic lung disease including bronchopulmonary dysplasia
- Failure to obtain an informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Heliox group Heliox receive Helium oxygen mixture 21:79 via nasal cannula 2L/min Air group Air receive oxygen 21%via nasal cannula 2L/min
- Primary Outcome Measures
Name Time Method Improvement in oxygenation change from baseline at 24 hours after treatment Arterial blood samples will be withdrawn through an arterial stab to determine partial pressure of arterial oxygen (PaO2)
- Secondary Outcome Measures
Name Time Method improvement of respiratory distress change from baseline at 24 hours after treatment measured by the Modified Wood's Clinical Asthma Score